TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of “Moderate Buy” by Brokerages

by · The Cerbat Gem

TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $29.00.

Several equities analysts recently issued reports on TGTX shares. StockNews.com cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. B. Riley upped their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $39.00 target price on shares of TG Therapeutics in a report on Thursday.

View Our Latest Research Report on TG Therapeutics

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds have recently bought and sold shares of TGTX. Cim Investment Management Inc. grew its holdings in TG Therapeutics by 3.6% in the first quarter. Cim Investment Management Inc. now owns 15,521 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 535 shares during the last quarter. New York State Common Retirement Fund increased its holdings in TG Therapeutics by 1.2% during the 4th quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock valued at $960,000 after acquiring an additional 663 shares in the last quarter. Kestra Advisory Services LLC raised its position in TG Therapeutics by 8.2% during the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 1,240 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of TG Therapeutics by 3.5% in the third quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 1,356 shares in the last quarter. Finally, Valeo Financial Advisors LLC grew its position in shares of TG Therapeutics by 2.5% in the third quarter. Valeo Financial Advisors LLC now owns 61,800 shares of the biopharmaceutical company’s stock valued at $517,000 after purchasing an additional 1,500 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Trading Down 1.5 %

TGTX opened at $13.78 on Friday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 689.00 and a beta of 2.30. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $35.67. The business’s 50 day moving average is $15.11 and its two-hundred day moving average is $13.95. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. The firm had revenue of $43.97 million during the quarter, compared to analysts’ expectations of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same quarter in the prior year, the business earned ($0.39) EPS. On average, research analysts predict that TG Therapeutics will post -0.12 EPS for the current year.

TG Therapeutics Company Profile

(Get Free Report

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Read More